Isotretinoin

Active ingredient: Isotretinoin

In short: Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, isotretinoin capsules

Forms & strengthsIsotretinoin capsules, USP are available in 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg capsules. 10 mg: Hard gelatin capsule with gold opaque cap and gold opaque body printed “A1254” on cap and “10” on body with black ink. …
LabelAmneal Pharmaceuticals LLC
Label updatedNov 06, 2026

What is Isotretinoin used for?

Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, isotretinoin capsules are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.

Limitations of Use:

If a second course of isotretinoin capsules treatment is needed, it is not recommended before a 2-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of treatment .

âš  Boxed warning (FDA's strongest warning)

Isotretinoin can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of isotretinoin even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. If pregnancy occurs, discontinue isotretinoin immediately and refer the patient to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling [see Contraindications (4), Warnings and Precautions (5.1), and

Use in Specific Populations (8.1)].

Because of the risk of embryo-fetal toxicity, isotretinoin are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE REMS .

Isotretinoin dosage

In patients who can get pregnant, only prescribe isotretinoin capsules after verification and documentation that they are not pregnant . For the detailed requirements prior to prescribing isotretinoin capsules, .

Prior to isotretinoin capsules use in all patients, complete the following laboratory testing:

A fasting lipid profile including triglycerides .

Liver function tests .

Isotretinoin capsules are not substitutable with ABSORICA LD . The recommended dosage of:

Isotretinoin capsules are 0.5 to 1 mg/kg/day given in two divided doses with or without meals for 15 to 20 weeks .

To decrease the risk of esophageal irritation, instruct patients to swallow the capsules with a full glass of liquid. Swallow capsules whole. Do not split, crush, chew, or suck on the capsules.

During treatment, the dosage may be adjusted according to response of the disease and/or adverse reactions, some of which may be dose-related. Adult patients whose disease is very severe with scarring or primarily manifested on the trunk may require dosage adjustments up to 2 mg/kg/day for isotretinoin capsules in divided doses, as tolerated.

The safety and effectiveness of once daily dosing with isotretinoin capsules have not been established and is not recommended.

If a dose of isotretinoin capsules are missed, just skip that dose. Do not take two doses of isotretinoin capsules at the same time.

Table 1: Isotretinoin Capsules Daily Dosage by Body Weight1

Body Weight | Total Daily Dosage (mg)1

0.5 mg/kg | 1 mg/kg | 2 mg/kg

40 kg | 20 | 40 | 80

50 kg | 25 | 50 | 100

60 kg | 30 | 60 | 120

70 kg | 35 | 70 | 140

80 kg | 40 | 80 | 160

90 kg | 45 | 90 | 180

100 kg | 50 | 100 | 200

1 Administer in two divided doses with or without meals

A normal course of treatment is 15 to 20 weeks. If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, may discontinue isotretinoin capsules.

After a period of 2 months or more off treatment, and if warranted by persistent or recurring severe nodular acne, may initiate a second course of isotretinoin capsules in patients who have completed skeletal growth. The use of another course of isotretinoin capsules treatment is not recommended before a 2-month waiting period because the patient’s acne may continue to improve after a 15 to 20-week course of treatment. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth.

Long-term use of isotretinoin capsules, even in low dosages, has not been studied, and is not recommended. The effect of long-term use of isotretinoin capsules on bone loss is unknown .

How to take Isotretinoin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Embryo-Fetal Toxicity

There is an extremely high risk of life-threatening birth defects when isotretinoin is used in pregnancy . Instruct patients who can become pregnant that they must not be pregnant during or up to 1 month after isotretinoin treatment. Instruct patients to not donate blood during isotretinoin treatment and for 1 month following discontinuation to avoid blood donation to a pregnant patient.

iPLEDGE REMS

Isotretinoin is available only through a restricted program called the iPLEDGE REMS . Inform patients who can get pregnant of the following notable requirements. These patients must:

Enroll in the REMS

Comply with REMS requirements including:

Comply with the pregnancy testing and pregnancy prevention requirements .

Demonstrate comprehension of the risk and REMS requirements prior to each prescription.

Obtain the prescription within 7-day prescription window (i.e., within the 7 days of the pregnancy test collection).

Inform their prescriber if they get pregnant and stop treatment.

Inform patients who cannot get pregnant of the following notable requirements. …

Warnings & precautions

Do not take this medicine if: Isotretinoin is contraindicated in:

Pregnancy .

Patients with hypersensitivity to isotretinoin (or Vitamin A, given the chemical similarity to isotretinoin) or to any of its components (anaphylaxis and other allergic reactions have occurred) .

Isotretinoin is contraindicated in pregnancy . Based on human data, isotretinoin can cause fetal harm when administered to a pregnant patient. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of isotretinoin even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. Major congenital malformations, spontaneous abortions, and premature births have been documented following exposure to isotretinoin during pregnancy .

If a pregnancy occurs during isotretinoin treatment, immediately discontinue isotretinoin and refer the patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Immediately report any suspected fetal exposure during or 1 month after isotretinoin treatment to the FDA via the MedWatch telephone number 1-800-FDA-1088, and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (www.ipledgeprogram.com).

Inform patients not to donate blood during isotretinoin treatment and for 1 month following discontinuation because the blood might be given to a pregnant patient whose fetus must not be exposed to isotretinoin.

Isotretinoin is available only through a restricted program under a REMS .

Because of the risk of embryo-fetal toxicity, isotretinoin are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE REMS . …

Isotretinoin side effects

The following adverse reactions with isotretinoin or other isotretinoin capsule products are described in more detail in other sections of the labeling:

Embryo-Fetal Toxicity

Psychiatric Disorders

Intracranial Hypertension (Pseudotumor Cerebri)

Serious Skin Reactions

Pancreatitis

Lipid Abnormalities

Hearing Impairment

Hepatotoxicity

Inflammatory Bowel Disease

Musculoskeletal Abnormalities

Ocular Abnormalities

Hypersensitivity Reactions

The following adverse reactions associated with the use of isotretinoin capsules were identified in clinical trials or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Dose Relationship

Cheilitis and hypertriglyceridemia were dose related.

Body as a Whole

Fatigue, irritability, pain, allergic reactions, systemic hypersensitivity, edema, lymphadenopathy, weight loss.

Cardiovascular

Vascular thrombotic disease, stroke, palpitation, tachycardia.

Endocrine/Metabolism and Nutritional

Decreased appetite, weight fluctuation, alterations in blood sugar.

Gastrointestinal

Dry lips, chapped lips, cheilitis, nausea, constipation, diarrhea, abdominal pain, vomiting, inflammatory bowel disease, hepatitis, pancreatitis, bleeding and inflammation of the gums, colitis, esophagitis, esophageal ulceration, ileitis. …

Drug interactions

Avoid concomitant use of isotretinoin with supplements containing vitamin A.

Isotretinoin is closely related to vitamin A. Therefore, concomitant use of isotretinoin with vitamin A may lead to isotretinoin-associated adverse reactions.

Avoid concomitant use of isotretinoin with tetracyclines because isotretinoin use has been associated with a number of cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines .

Isotretinoin capsules did not result in clinically significant changes in the pharmacokinetics of norethindrone and ethinyl estradiol when used concomitantly with a norethindrone and ethinyl estradiol oral contraceptive . It is not known if there is an interaction with the concomitant use of isotretinoin with other oral contraceptives.

About this medicine

Isotretinoin Capsules, USP

Isotretinoin capsules, USP contain 10 mg, 20 mg, 25 mg, 30 mg, 35 mg or 40 mg of isotretinoin, USP (a retinoid) in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin USP, each capsule contains the following inactive ingredients: propyl gallate, sorbitan monooleate, soybean oil and stearoyl polyoxylglycerides. The gelatin capsules contain the following dye systems:

10 mg – D&C yellow #10, FD&C yellow #6, FD&C red #40, FD&C blue #1 and titanium dioxide

20 mg – iron oxide (red), FD&C red #40, FD&C blue #1 and titanium dioxide

25 mg – FD&C Yellow #6, FD&C blue #1 and titanium dioxide

30 mg – D&C yellow #10, FD&C red #40, FD&C blue #1 and titanium dioxide

35 mg – FD&C Yellow #6, FD&C red #40, FD&C Blue #1 and titanium dioxide

40 mg – iron oxide (black, red and yellow), FD&C red #40, FD&C Blue #1 and titanium dioxide

The black imprinting ink of 10 mg and 20 mg capsules contains the following ingredients: shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, ammonia solution (strong ammonia …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9f1c8971-c6dc-4708-848b-5cee50b6c32a. Read the full official label on DailyMed.

Related medicines

Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Brimonidine Dupilumab